

118TH CONGRESS
2D SESSION

H. R. 9807

To amend the Public Health Service Act to authorize a grant program to provide surge capacity for providers faced with increased unmet need for contraceptive care.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 25, 2024

Ms. CARAVEO (for herself, Ms. LOIS FRANKEL of Florida, Ms. WILLIAMS of Georgia, Ms. MANNING, Mrs. PELTOLA, Ms. BROWNLEY, Ms. NORTON, Ms. BUSH, Mr. GRIJALVA, Mr. GOTTHEIMER, Mr. ALLRED, Ms. PETERSEN, and Ms. TITUS) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to authorize a grant program to provide surge capacity for providers faced with increased unmet need for contraceptive care.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Strengthening Access
5 to Contraceptive Care Act”.

6 **SEC. 2. FINDINGS.**

7 Congress finds the following:

1 (1) Nearly 9 in 10 women of reproductive age
2 have used contraception, and nearly 9 in 10 adults
3 agree that everyone deserves access to the full range
4 of birth control methods, no matter who they are,
5 where they live, or their economic status.

6 (2) More than 19,000,000 women, plus more
7 transgender and nonbinary individuals, of reproduc-
8 tive age in the United States live in contraceptive
9 deserts, meaning they lack reasonable access in their
10 county to a health center offering the full range of
11 contraceptive methods.

12 (3) Additionally, 1,200,000 of such women live
13 in a county without a single health center offering
14 the full range of contraceptive methods.

15 (4) Research shows that Black women are more
16 likely to live in a contraceptive desert, and face bar-
17 riers accessing pharmacies.

18 (5) Systemic racism, discrimination, and lack of
19 access to comprehensive sex education exacerbates
20 severe health inequities and creates additional bar-
21 riers to accessing contraception.

22 (6) Due to high uninsured rates and barriers,
23 Hispanic women with low incomes experience a sig-
24 nificantly higher rate of unintended pregnancy, of 58

1 percent, compared to their White counterparts, with
2 a rate of 33 percent.

3 (7) A 2023 study found that among people who
4 identified as Asian American, Native Hawaiian, or
5 Pacific Islander, Black or African American, Indige-
6 nous, Latina, or Latinx, 45 percent of respondents
7 reported experiencing at least one challenge access-
8 ing contraception in the past year.

9 (8) To address the challenges in accessing con-
10 traceptive care, proper investments need to be made
11 to improve availability to such care nationwide, with
12 a particular focus in the counties where health cen-
13 ters currently do not offer the full range of methods.

14 (9) The family planning safety net has been
15 chronically underfunded and is in dire need of sig-
16 nificant additional investment. The family planning
17 program under title X of the Public Health Service
18 Act (42 U.S.C. 300 et seq.) has been funded at the
19 same level for a decade, and needs more than 3
20 times the current funding level to meet the dem-
21 onstrated need. However, even if such program were
22 fully funded, there would still be factors that strain
23 provider capacity and limit the ability to meet the
24 needs of contraception patients.

1 **SEC. 3. GRANTS TO INCREASE ACCESS TO CONTRACEPTIVE**
2 **CARE.**

3 Subpart V of part D of title III of the Public Health
4 Service Act (42 U.S.C. 256 et seq.) is amended by adding
5 at the end the following:

6 **“SEC. 340A-1. GRANTS TO INCREASE ACCESS TO CONTRA-**
7 **CEPTIVE CARE.**

8 “(a) IN GENERAL.—The Secretary shall carry out a
9 grant program consisting of awarding grants to eligible
10 entities to increase their capacity to provide contraceptive
11 care to individuals seeking to access contraceptive care
12 within or outside of their States of residence.

13 “(b) ELIGIBLE ENTITIES.—To be eligible to receive
14 a grant under this section, an entity shall—

15 “(1) be a hospital, clinic, or other health care
16 facility, university, nonprofit organization, commu-
17 nity-based organization, State or local governmental
18 entity, or Tribal government that, through pro-
19 grams, services, or activities that are unbiased and
20 medically and factually accurate—

21 “(A) provides or refers for abortion serv-
22 ices; or

23 “(B) provides unbiased information and
24 counseling about abortion; and

1 “(2) be in a State, the District of Columbia, or
2 a commonwealth, territory, or possession of the
3 United States.

4 “(c) PRIORITY.—In awarding grants under this sec-
5 tion, the Secretary shall give priority to eligible entities—

6 “(1) in States that, as determined by the Sec-
7 retary, can demonstrate an increased unmet need for
8 contraceptive services; and

9 “(2) which, as of the date of the enactment of
10 this Act, have received a grant under title X of the
11 Public Health Service Act (42 U.S.C. 300 et seq.).

12 “(d) AUTHORIZED ACTIVITIES.—A grant under this
13 section may be used for any of the following supplies,
14 equipment, or services related to providing contraceptive
15 care:

16 “(1) Providing patient education on all methods
17 of contraception approved, granted marketing au-
18 thorization, or cleared under the Federal Food
19 Drug, and Cosmetic Act, or licensed under section
20 351 of this Act.

21 “(2) Purchasing of contraceptive supplies, in-
22 cluding emergency contraception.

23 “(3) Providing person-centered contraceptive
24 counseling.

1 “(4) Based on the outcome of counseling under
2 paragraph (3), as the patient is interested, provide
3 contraception free from coercion, including hormonal
4 contraception medication and devices, barrier contra-
5 ception, and emergency contraception.

6 “(5) Administering telehealth services, which
7 may include audio, video, and text messaging serv-
8 ices.

9 “(6) Contracting or hiring clinical and nonclin-
10 ical support staff, and other relevant health care
11 personnel.

12 “(7) Creating and disseminating medically-ac-
13 curate, culturally- and linguistically-appropriate, ac-
14 cessible educational materials and resources on con-
15 traception and contraceptive care for patients.

16 “(8) Interpretation and translation services.

17 “(9) Contraception referrals and counseling.

18 “(10) Follow-up contraceptive care, including
19 the management, evaluation, and changes, including
20 the removal, continuation, and discontinuation, of
21 contraception.

22 “(e) APPLICATION.—To seek a grant under this sec-
23 tion, an eligible entity shall submit an application to the
24 Secretary at such time, in such manner, and containing
25 such information as the Secretary may require, including

1 a plan for increasing capacity as described in subsection
2 (a).

3 “(f) PROHIBITION AGAINST EXCLUSION OF QUALI-
4 FIED ELIGIBLE ENTITIES.—No Federal agency, grantee,
5 subrecipient, or other entity shall, in the course of admin-
6 istering or carrying out any program or activity under this
7 section, act in a manner which has the effect of excluding,
8 limiting, or restricting the participation of any entity that
9 would otherwise be eligible to apply for funds, on the basis
10 of any factor unrelated to the entity’s qualifications to ef-
11 fectively carry out the program or activity.

12 “(g) DEFINITIONS.—In this section:

13 “(1) CONTRACEPTIVE CARE.—The term ‘con-
14 traceptive care’ means education, person-centered
15 counseling, and provision of any method of contra-
16 ception approved, granted marketing authorization,
17 or cleared under the Federal Food Drug, and Cos-
18 metic Act, or licensed under section 351 of this Act,
19 including emergency contraception.

20 “(2) CONTRACEPTION.—The term ‘contracep-
21 tion’ means a device, medication, procedure, or be-
22 havior that is intended to prevent pregnancy. Such
23 term includes any device, medication, procedure, or
24 behavior listed in the most recently published Birth

1 Control Guide published by the Food and Drug Ad-
2 ministration, including—

3 “(A) sterilization surgery for women;

4 “(B) implantable rods;

5 “(C) copper intrauterine devices;

6 “(D) intrauterine devices with progestin;

7 “(E) injectable contraceptives;

8 “(F) oral contraceptives (combined pill);

9 “(G) oral contraceptives (progestin only);

10 “(H) oral contraceptives (extended or con-
11 tinuous use);

12 “(I) contraceptive patch;

13 “(J) vaginal contraceptive rings;

14 “(K) diaphragms;

15 “(L) contraceptive sponges;

16 “(M) cervical caps;

17 “(N) condoms;

18 “(O) spermicides;

19 “(P) emergency contraception
20 (levonorgestrel);

21 “(Q) emergency contraception (ulipristal
22 acetate); and

23 “(R) any additional contraceptives ap-
24 proved, granted marketing authorization, or
25 cleared under the Federal Food, Drug, and

1 Cosmetic Act or licensed under section 351 of
2 this Act.

3 “(h) AUTHORIZATION OF APPROPRIATIONS.—To
4 carry out this section, there is authorized to be appro-
5 priated \$100,000,000 for each of fiscal years 2025
6 through 2029.”.

○